800 - 460 - 5832


Big news for OPDIVO®!
Mar 3, 2017

Big news announcing BC will cover the cost of the immuno-oncology treatment OPDIVO® for the treatment of eligible patients who have metastatic melanoma, locally advanced or metastatic pre-treated non-small cell lung cancer (NSCLC) and advanced or metastatic pre-treated renal cell carcinoma (RCC).

This news comes following the agreement signed last month with the pan-Canadian Pharmaceutical Alliance (pCPA). Yukon also recently agreed to cover treatment with OPDIVO® for these three tumour types, making it the first Canadian territory to do so.

Read the full press release here!

Share Button